(Q37714306)

22 August 2017

1 reference

title

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents (English)

1 reference

22 August 2017

0 references

2

Daniel A Haber

1 reference

22 August 2017

Sreenath V Sharma

1

1 reference

22 August 2017

Jeff Settleman

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

19 March 2010

1 reference

22 August 2017

Nature Reviews Cancer

1 reference

22 August 2017

10

1 reference

22 August 2017

241-253

1 reference

22 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2820

22 August 2017

0 references

cites work

RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels

1 reference

The response to chemotherapy of a variety of human tumour xenografts

21 January 2018

1 reference

Maximizing mouse cancer models

21 January 2018

1 reference

Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA.

21 January 2018

1 reference

The NCI60 human tumour cell line anticancer drug screen

21 January 2018

1 reference

Cisplatin as first-line therapy for metastatic breast cancer

31 March 2020

1 reference

High-dose etoposide in treatment of metastatic breast cancer.

31 March 2020

1 reference

Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin

31 March 2020

1 reference

A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer

31 March 2020

1 reference

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

31 March 2020

1 reference

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

31 March 2020

1 reference

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

31 March 2020

1 reference

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

31 March 2020

1 reference

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

31 March 2020

1 reference

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

31 March 2020

1 reference

Metastatic pancreatic cancer 2008: is the glass less empty?

31 March 2020

1 reference

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

31 March 2020

1 reference

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

31 March 2020

1 reference

Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck

31 March 2020

1 reference

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

31 March 2020

1 reference

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

31 March 2020

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

31 March 2020

1 reference

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

31 March 2020

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

Sorafenib in advanced hepatocellular carcinoma

31 March 2020

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

31 March 2020

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

31 March 2020

1 reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

31 March 2020

1 reference

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

31 March 2020

1 reference

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

31 March 2020

1 reference

Mutations of the BRAF gene in human cancer

31 March 2020

1 reference

Cancer. Addiction to oncogenes--the Achilles heal of cancer

31 March 2020

1 reference

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

31 March 2020

1 reference

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

31 March 2020

1 reference

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

31 March 2020

1 reference

The concept of synthetic lethality in the context of anticancer therapy

31 March 2020

1 reference

Lineage dependency and lineage-survival oncogenes in human cancer

31 March 2020

1 reference

Principles of cancer therapy: oncogene and non-oncogene addiction

31 March 2020

1 reference

Epidermal growth factor receptor mutations in lung cancer

31 March 2020

1 reference

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

31 March 2020

1 reference

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

31 March 2020

1 reference

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions

31 March 2020

1 reference

High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor

31 March 2020

1 reference

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

31 March 2020

1 reference

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

31 March 2020

1 reference

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

31 March 2020

1 reference

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

31 March 2020

1 reference

Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors

31 March 2020

1 reference

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

31 March 2020

1 reference

The increasing complexity of the cancer stem cell paradigm

31 March 2020

1 reference

Mechanisms of Disease: cancer stem cells--targeting the evil twin

31 March 2020

1 reference

Mapping normal and cancer cell signalling networks: towards single-cell proteomics

31 March 2020

1 reference

Non-genetic heterogeneity--a mutation-independent driving force for the somatic evolution of tumours.

31 March 2020

1 reference

Leukaemogenesis: more than mutant genes

31 March 2020

1 reference

Modeling genomic diversity and tumor dependency in malignant melanoma

31 March 2020

1 reference

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

31 March 2020

1 reference

Integrated analysis of breast cancer cell lines reveals unique signaling pathways

31 March 2020

1 reference

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

31 March 2020

1 reference

A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.

31 March 2020

1 reference

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

31 March 2020

1 reference

Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells

31 March 2020

1 reference

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

31 March 2020

1 reference

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

31 March 2020

1 reference

Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells

31 March 2020

1 reference

Systematic discovery of multicomponent therapeutics

31 March 2020

1 reference

Synergistic drug combinations tend to improve therapeutically relevant selectivity

31 March 2020

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

31 March 2020

1 reference

p53 alterations in human leukemia-lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization?

31 March 2020

1 reference

Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies

31 March 2020

1 reference

Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology

31 March 2020

1 reference

Taking the study of cancer cell survival to a new dimension

31 March 2020

1 reference

Cell culture: biology's new dimension

31 March 2020

1 reference

Capturing complex 3D tissue physiology in vitro

31 March 2020

1 reference

Modeling tissue morphogenesis and cancer in 3D.

31 March 2020

1 reference

Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis

31 March 2020

1 reference

Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis

31 March 2020

1 reference

Spheroid-based drug screen: considerations and practical approach

31 March 2020

1 reference

In vivo cultivation of tumor cells in hollow fibers

31 March 2020

1 reference

Xenotransplantation of canine, bovine, and porcine islets in diabetic rats without immunosuppression

31 March 2020

1 reference

Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets

31 March 2020

1 reference

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

31 March 2020

1 reference

The hollow fibre model in cancer drug screening: the NCI experience

31 March 2020

1 reference

To create the correct microenvironment: three-dimensional heterotypic collagen assays for human breast epithelial morphogenesis and neoplasia

31 March 2020

1 reference

Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation

31 March 2020

1 reference

Three-dimensional culture models of normal and malignant breast epithelial cells

31 March 2020

1 reference

Experimental anti-tumor therapy in 3-D: spheroids--old hat or new challenge?

31 March 2020

1 reference

Relations between pH, oxygen partial pressure and growth in cultured cell spheroids.

31 March 2020

1 reference

Spheroids in radiobiology and photodynamic therapy

31 March 2020

1 reference

Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids

31 March 2020

1 reference

Establishment and characterization of multicellular spheroids from a human glioma cell line; Implications for tumor therapy

31 March 2020

1 reference

The use of 3-D cultures for high-throughput screening: the multicellular spheroid model

31 March 2020

1 reference

Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant

31 March 2020

1 reference

Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death

31 March 2020

1 reference

Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells

31 March 2020

1 reference

Hyaluronan hydrogel: an appropriate three-dimensional model for evaluation of anticancer drug sensitivity

31 March 2020

1 reference

Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer

31 March 2020

1 reference

The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures

31 March 2020

1 reference

Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids

31 March 2020

1 reference

A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay

31 March 2020

1 reference

Multicellular spheroids. A review on cellular aggregates in cancer research

31 March 2020

1 reference

Comparison of protein expression profiles between monolayer and spheroid cell culture of HT-29 cells revealed fragmentation of CK18 in three-dimensional cell culture

31 March 2020

1 reference

Identification of genes differentially expressed in V79 cells grown as multicell spheroids

31 March 2020

1 reference

Identification of differentially expressed genes involved in the formation of multicellular tumor spheroids by HT-29 colon carcinoma cells.

31 March 2020

1 reference

Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery

31 March 2020

1 reference

Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts

31 March 2020

1 reference

Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA.

31 March 2020

1 reference

Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development

31 March 2020

1 reference

Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development

31 March 2020

1 reference

The use of GEM models for experimental cancer therapeutics

31 March 2020

1 reference

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

31 March 2020

1 reference

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

31 March 2020

1 reference

A gene expression database for the molecular pharmacology of cancer

31 March 2020

1 reference

Neural computing in cancer drug development: predicting mechanism of action

31 March 2020

1 reference

Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents.

31 March 2020

1 reference

An information-intensive approach to the molecular pharmacology of cancer.

31 March 2020

1 reference

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen

31 March 2020

1 reference

Proteasome inhibition in cancer: development of PS-341.

31 March 2020

1 reference

Update on NCI in vitro drug screen utilities

31 March 2020

1 reference

Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics

31 March 2020

1 reference

Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor

31 March 2020

1 reference

Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform.

31 March 2020

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

31 March 2020

1 reference

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

31 March 2020

1 reference

Lung cancer: intragenic ERBB2 kinase mutations in tumours

31 March 2020

1 reference

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

31 March 2020

1 reference

Genetic predictors of MEK dependence in non-small cell lung cancer

31 March 2020

1 reference

PIK3CA mutations and copy number gains in human lung cancers

31 March 2020

1 reference

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma

31 March 2020

1 reference

The National Cancer Chemotherapy Program

31 March 2020

1 reference

Differential in vitro effects of chemotherapeutic agents on primary cultures of human ovarian carcinoma

31 March 2020

1 reference

12 December 2020

In vitro responses of ovarian cancers to platinums and taxanes

1 reference

12 December 2020

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors

1 reference

12 December 2020

Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel

1 reference

12 December 2020

The National Cancer Institute: cancer drug discovery and development program

1 reference

12 December 2020

Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).

1 reference

12 December 2020

Microencapsulated tumor assay: new short-term assay for in vivo evaluation of the effects of anticancer drugs on human tumor cell lines.

1 reference

12 December 2020

Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved

1 reference

12 December 2020

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay

1 reference

12 December 2020

50 years of preclinical anticancer drug screening: empirical to target-driven approaches.

1 reference

12 December 2020

Why drugs fail: of mice and men revisited

1 reference

12 December 2020

Three-dimensional cell cultures: from molecular mechanisms to clinical applications

1 reference

12 December 2020

An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines

1 reference

12 December 2020

The hollow fiber assay: continued characterization with novel approaches.

1 reference

12 December 2020

Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy

1 reference

12 December 2020

BRAF and RAS mutations in human lung cancer and melanoma

1 reference

12 December 2020

Breast cancer--response rates to chemotherapeutic agents studied in vitro.

1 reference

12 December 2020

Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen

1 reference

12 December 2020

Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.

1 reference

12 December 2020

The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets

1 reference

12 December 2020

Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays

1 reference

12 December 2020

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

12 December 2020

FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis.

1 reference

12 December 2020

Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer.

1 reference

12 December 2020

Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

1 reference

12 December 2020

Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC2820

1 reference

Dimensions Publication ID

22 August 2017

1012705094

0 references

Fatcat ID

release_homc7aysc5adpgesdgifpp47eu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/homc7aysc5adpgesdgifpp47eu

24 November 2022

mapped directly with Wikidata item

1 reference